Actionable news
0
All posts from Actionable news
Actionable news in ACHN: Achillion Pharmaceuticals, Inc.,

Janssen readies mid-stage study of short duration HCV combo regimen for genotypes 1-6

Janssen Pharmaceuticals' (NYSE:JNJ) Janssen Research & Development, LLC initiates a Phase 2b clinical trial assessing the safety, pharmacokinetics and efficacy of different regimens of AL-335, odalasvir and simeprevir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1-6...


More